다발성 골수종 시장 : 예측(2026-2031년)

Multiple Myeloma Market is projected to expand at a 6.22% CAGR, reaching USD 37.67 billion in 2031 from USD 26.231 billion in 2025.

The multiple myeloma market represents a dynamic and rapidly evolving segment within hematological oncology, focused on a malignancy of plasma cells in the bone marrow. Characterized by a high relapse rate and the development of treatment resistance, the disease necessitates a continuous pipeline of novel therapeutic approaches, making this market a hub for significant clinical research and pharmaceutical investment.

Core Clinical Challenge and Therapeutic Paradigm

Multiple myeloma remains an incurable but increasingly treatable cancer, with management strategies centered on achieving deep and durable remissions, controlling symptoms, and preserving quality of life. The therapeutic landscape has shifted dramatically from reliance on traditional chemotherapy and corticosteroids to a multifaceted arsenal including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and, most recently, advanced cellular and bispecific immunotherapies. Treatment is typically administered in sequences, with regimens selected based on patient fitness, disease risk stratification, and prior therapy, reflecting a complex and personalized approach to care.

Primary Market Growth Drivers

Market expansion is fundamentally driven by the rising global incidence of the disease, which is strongly correlated with an aging population. As the predominant risk factor, increasing age ensures a growing addressable patient population, particularly in developed economies with aging demographics. This demographic trend provides a sustained baseline demand for effective therapies.

The most powerful growth vector, however, is the accelerated pace of therapeutic innovation and new drug approvals. The regulatory landscape has been highly active, with approvals for novel mechanisms of action, including B-cell maturation antigen (BCMA)-targeted therapies such as bispecific T-cell engagers and chimeric antigen receptor (CAR) T-cell therapies. These approvals continually expand the treatment repertoire for relapsed/refractory disease and are progressively moving into earlier lines of therapy, significantly lengthening treatment pathways and driving market value.

Increased disease awareness and earlier diagnosis also contribute to market growth. Educational initiatives by patient advocacy groups and professional societies have improved recognition of symptoms among primary care providers and the public, leading to earlier specialist referral and diagnosis. Earlier intervention in the disease course expands the window for effective treatment and improves long-term outcomes, thereby integrating more patients into active, long-term management pathways.

Substantial and ongoing investment in biomedical research underpins the market's evolution. A deepening understanding of disease biology, tumor microenvironment interactions, and mechanisms of resistance is translating into a rich pipeline of targeted agents and immunotherapies. This research is supported by significant funding from both public institutions and private pharmaceutical companies, fostering a competitive and innovative environment.

Market Opportunities and Evolving Frontiers

Key opportunities for future growth lie in several areas. The frontier of treatment is increasingly focused on earlier lines of therapy, including newly diagnosed and even high-risk smoldering myeloma, aiming to prevent progression. The development of personalized treatment strategies, guided by genomic profiling and minimal residual disease (MRD) monitoring, represents a major opportunity to optimize outcomes and tailor therapy intensity.

Furthermore, the market is poised for expansion through improved access and adoption in emerging economies, where diagnosis and treatment infrastructure are developing. The exploration of novel drug combinations and sequencing strategies to overcome resistance and deepen responses remains a central focus of clinical development.

Market Restraints and Clinical Hurdles

The market faces significant inherent challenges. The development of treatment resistance remains a fundamental biological obstacle, limiting the long-term efficacy of all current therapies and necessitating a continuous pipeline of novel agents. The complexity and heterogeneity of the disease, with numerous genetic subtypes, complicate the development of universally effective treatments.

Furthermore, the toxicity profiles of newer, more potent therapies-including cytokine release syndrome, neurotoxicity, and prolonged cytopenias-present substantial management challenges. These toxicities can impact patient quality of life, require specialized clinical support, and limit the applicability of therapies in frail or elderly populations.

Geographic Landscape and Regional Dynamics

North America maintains a leadership position in the global multiple myeloma market. This is attributable to a high disease prevalence, a robust clinical trial infrastructure that facilitates rapid adoption of new therapies, favorable reimbursement landscapes, and the presence of leading research institutions and pharmaceutical companies. The region often serves as the initial launch market and primary revenue generator for innovative, high-cost therapies.

Competitive Landscape and Strategic Focus

The competitive environment is intense and features both large multinational pharmaceutical companies and specialized biotechnology firms. Strategic activities are centered on extensive research and development to advance next-generation therapies, including novel CAR-T constructs, bispecific antibodies with new targets, and antibody-drug conjugates.

Companies are heavily invested in large-scale clinical trials to move their agents into earlier treatment lines and secure dominant positions in therapeutic sequences. Lifecycle management for established drugs, through new combination studies or subcutaneous formulations, is also a key strategy. Collaboration and licensing agreements between large pharma and biotech innovators are common, accelerating development and commercialization.

Future Market Trajectory

The future trajectory of the multiple myeloma market is oriented toward increasingly sophisticated immunotherapy, functional cure as a treatment goal, and greater personalization. The development of therapies with novel targets beyond BCMA is already underway. The integration of cellular therapies and bispecific antibodies into first-line treatment paradigms will redefine standards of care.

Long-term success for market participants will depend on demonstrating superior efficacy and manageable safety in competitive landscapes, navigating complex reimbursement pathways for high-cost therapies, and developing strategies to address treatment resistance. As a model for innovation in oncology, the multiple myeloma market is characterized by relentless scientific advancement aimed at transforming a once devastating diagnosis into a chronic, manageable condition, ensuring its continued expansion and evolution.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Multiple Myeloma Market Segmentation

• By Type
• Smouldering Multiple Myeloma
• Active Multiple Myeloma
• By Treatment
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Stem Cell Transplantation
• Corticosteroids
• By Diagnosis
• Blood Tests
• Bone Marrow Biopsy
• Urine Tests
• By End-User
• Hospitals & Clinics
• Homecare
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MULTIPLE MYELOMA MARKET BY TYPE

• 5.1. Introduction
• 5.2. Smouldering Multiple Myeloma
• 5.3. Active Multiple Myeloma

6. MULTIPLE MYELOMA MARKET BY TREATMENT

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Targeted Therapy
• 6.4. Immunotherapy
• 6.5. Stem Cell Transplantation
• 6.6. Corticosteroids

7. MULTIPLE MYELOMA MARKET BY DIAGNOSIS

• 7.1. Introduction
• 7.2. Blood Tests
• 7.3. Bone Marrow Biopsy
• 7.4. Urine Tests

8. MULTIPLE MYELOMA MARKET BY END-USER

• 8.1. Introduction
• 8.2. Hospitals & Clinics
• 8.3. Homecare
• 8.4. Others

9. MULTIPLE MYELOMA MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Diagnosis
  • 9.2.4. By End-User
  • 9.2.5. By Country
    • 9.2.5.1. USA
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. South America
  • 9.3.1. By Type
  • 9.3.2. By Treatment
  • 9.3.3. By Diagnosis
  • 9.3.4. By End-User
  • 9.3.5. By Country
    • 9.3.5.1. Brazil
    • 9.3.5.2. Argentina
    • 9.3.5.3. Others
• 9.4. Europe
  • 9.4.1. By Type
  • 9.4.2. By Treatment
  • 9.4.3. By Diagnosis
  • 9.4.4. By End-User
  • 9.4.5. By Country
    • 9.4.5.1. United Kingdom
    • 9.4.5.2. Germany
    • 9.4.5.3. France
    • 9.4.5.4. Spain
    • 9.4.5.5. Others
• 9.5. Middle East and Africa
  • 9.5.1. By Type
  • 9.5.2. By Treatment
  • 9.5.3. By Diagnosis
  • 9.5.4. By End-User
  • 9.5.5. By Country
    • 9.5.5.1. Saudi Arabia
    • 9.5.5.2. UAE
    • 9.5.5.3. Others
• 9.6. Asia Pacific
  • 9.6.1. By Type
  • 9.6.2. By Treatment
  • 9.6.3. By Diagnosis
  • 9.6.4. By End-User
  • 9.6.5. By Country
    • 9.6.5.1. China
    • 9.6.5.2. Japan
    • 9.6.5.3. India
    • 9.6.5.4. South Korea
    • 9.6.5.5. Taiwan
    • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Revlimid
• 11.2. Bristol-Myers Squibb
• 11.3. Abecma
• 11.4. Novartis
• 11.5. Pomalyst
• 11.6. Takeda Pharmaceuticals
• 11.7. Johnson & Johnson
• 11.8. Innate Pharma
• 11.9. Janssen

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key Benefits for the Stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations